New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
Neovasc Stock Snapshot
2.75 M
Number of Shares
0.00
Dividend in USD
0.00
Dividend Yield
-19.62
EPS in USD
7.80
Book Value per Share in USD
-12.08
Cash Flow per Share in USD
Neovasc NewsMore News
Seeking Alpha
Neovasc GAAP EPS of -$15.07, revenue of $3.81M
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Benzinga
Nasdaq Edges Higher; Neovasc Shares Jump
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Benzinga
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
GainersCelyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
Neovasc Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 01/18/23 | H.C. Wainwright & Co. | Downgraded to Hold | neutral |
Neovasc Estimates* in EUR
| 2024 | 2025 | |
|---|---|---|
| Revenue | - | 22 |
| Dividend | - | - |
| Dividend Yield (in %) | - | - |
| EPS | - | -4.68 |
| P/E Ratio | -7.80 | - |
| EBIT | - | -19 |
| EBITDA | - | - |
| Net Profit | - | -21 |
| Net Profit Adjusted | - | - |
| Pre-Tax Profit | - | -21 |
| Net Profit (Adjusted) | - | - |
| EPS (Non-GAAP) ex. SOE | - | - |
| EPS (GAAP) | - | - |
| Gross Income | - | 18 |
| Cash Flow from Investing | - | - |
| Cash Flow from Operations | - | -29 |
| Cash Flow from Financing | - | -1 |
| Cash Flow per Share | - | - |
| Free Cash Flow | - | - |
| Free Cash Flow per Share | - | - |
| Book Value per Share | - | - |
| Net Debt | - | - |
| Research & Development Exp. | - | 5 |
| Capital Expenditure | - | - |
| Selling, General & Admin. Exp. | - | - |
| Shareholder’s Equity | - | 4 |
| Total Assets | - | 56 |
| Previous Quarter | Current Quarter | Next Quarter | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | -3.850 USD | -4.680 USD |
| Year Ago | - | - | - | - | -3.850 USD |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | 10 USD | 22 USD |
| Year Ago | - | - | - | - | 10 USD |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
| Sales | 4.95 | 3.19 | 2.63 | 2.78 | 2.27 | 6.99 | 12.60 |
| Change of sales in % | 55.10 | 21.65 | -5.42 | 22.44 | -67.59 | -44.50 | -0.79 |
| Gross profit on sales | 3.53 | 1.66 | 1.00 | 1.32 | 1.29 | 1.86 | 2.48 |
| Gross profit on sales change in % | 112.96 | 66.15 | -24.28 | 1.68 | -30.54 | -24.98 | -26.84 |
| Operating income | -43.69 | -36.84 | -46.79 | -39.73 | -33.75 | -38.60 | -31.34 |
| Operating income change in % | -18.61 | 21.27 | -17.78 | -17.71 | 12.57 | -23.18 | -12.88 |
| Income before tax | -53.61 | -31.10 | -39.19 | -46.58 | -139.90 | -29.11 | -114.33 |
| Income before tax change in % | -72.40 | 20.66 | 15.86 | 66.71 | -380.64 | 74.54 | -236.43 |
| Income after tax | -53.64 | -31.20 | -38.49 | -46.62 | -140.04 | -29.74 | -114.60 |
| Income after tax change in % | -71.91 | 18.93 | 17.43 | 66.71 | -370.95 | 74.05 | -235.10 |
Balance Sheet in Mio. USD
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 31.01 | 17.68 | 20.26 | 31.84 | 29.58 | 73.53 | 153.24 |
| Long-term liabilities per share | 6.31 | 4.21 | 9.07 | 36.60 | 163.12 | 9,915.45 | 0.00 |
| Equity | 21.46 | 65.97 | 2.52 | -18.73 | -13.20 | -45.70 | -20.74 |
| Equity change in % | -67.47 | 2,518.60 | - | -41.88 | 71.11 | -120.40 | -125.74 |
| Balance sheet total | 52.48 | 83.65 | 22.78 | 13.10 | 16.38 | 27.82 | 132.51 |
| Balance sheet total change in % | -37.27 | 267.27 | 73.81 | -20.00 | -41.13 | -79.00 | 55.80 |
Key Data in USD
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 1.81 | 1.27 | 3.94 | 10.66 | 40.03 | 2,145.08 | 4,670.44 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (ear end quote, diluted EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 40.90 | 78.86 | 11.06 | -142.94 | -80.60 | -164.25 | -15.65 |
| Debt ratio in % | 59.10 | 21.14 | 88.94 | 242.94 | 180.60 | 264.25 | 115.65 |
Neovasc Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2021 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2020 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2019 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2018 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2017 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2016 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2015 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2014 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2013 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2012 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2011 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2010 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
| 2009 | Neovasc Inc Registered Shs | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Neovasc Profile
Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.
Neovasc Shareholder
| Owner | in % |
|---|---|
| Tudor Investment Corp. | 6.75 |
| Black Maple Capital Management LP | 3.91 |
| Natixis SA | 1.81 |
| Douglas Glen Janzen | 1.42 |
| Yakira Capital Management, Inc. | 1.36 |
| MMCAP International Inc. SPC | 1.01 |
| Sio Capital Management LLC | 0.82 |
| CSS LLC | 0.75 |
| JBF Capital, Inc. | 0.73 |
| Quinn Opportunity Partners LLC | 0.73 |
| US Capital Wealth Advisors LLC | 0.68 |
| Paul L. Geyer | 0.67 |
| Renaissance Technologies LLC | 0.63 |
| Choreo LLC | 0.59 |
| Fredericus Antonius Colen | 0.58 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
